Cellular stress-induced up-regulation of FMRP promotes cell survival by modulating PI3K-Akt phosphorylation cascades

Journal of Biomedical Science

Volumn 18, Issue 1, 2011, Pages

  Jeon, Se Jin ^a   Seo, Jung Eun ^a   Yang, Sung Il ^d   Choi, Ji Woong ^e   Wells, David ^b   Shin, Chan Young ^c,d   Ko, Kwang Ho ^a  

^a Seoul National University   (South Korea)

^b YALE UNIVERSITY   (United States)

^c Neuroscience Research Center   (United States)

^d Konkuk University School of Medicine   (South Korea)

^e Gachon University College of Medicine   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ETOPOSIDE; FRAGILE X MENTAL RETARDATION PROTEIN; PHOSPHATIDYLINOSITOL 3 KINASE; PROPIDIUM IODIDE; PROTEIN BCL XL; PROTEIN KINASE B; SHORT HAIRPIN RNA; ANTINEOPLASTIC AGENT; BCL2L1 PROTEIN, HUMAN; FMR1 PROTEIN, HUMAN; PROTEIN BCL X;

APOPTOSIS; ARTICLE; BIOTECHNOLOGICAL PROCEDURES; CELL DEATH; CELL PROLIFERATION; CELL STRESS; CELL SURVIVAL; CELL VIABILITY; CONTROLLED STUDY; FEMALE; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION PROFILING; GENE OVEREXPRESSION; GENE SILENCING; GENE VECTOR; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; RECEPTOR UPREGULATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; WESTERN BLOTTING; BIOSYNTHESIS; DRUG EFFECT; FRAGILE X SYNDROME; GENETICS; METABOLISM; PHYSIOLOGICAL STRESS; UPREGULATION;

RNA VIRUSES;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; BCL-X PROTEIN; CELL SURVIVAL; ETOPOSIDE; FRAGILE X MENTAL RETARDATION PROTEIN; FRAGILE X SYNDROME; HELA CELLS; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; SIGNAL TRANSDUCTION; STRESS, PHYSIOLOGICAL; UP-REGULATION;

EID: 79751527394     PISSN: 10217770     EISSN: 14230127     Source Type: Journal    
DOI: 10.1186/1423-0127-18-17     Document Type: Article

References (51)

1. D'Hulst C, Kooy RF: Fragile X syndrome: from molecular genetics to therapy. J Med Genet 2009, 46(9):577-84.
2. Verheij C, Bakker CE, de Graaff E, Keulemans J, Willemsen R, Verkerk AJ, Galjaard H, Reuser AJ, Hoogeveen AT, Oostra BA: Characterization and localization of the FMR-1 gene product associated with fragile X syndrome. Nature 1993, 363(6431):722-4. (Pubitemid 23227649)
3. Tamanini F, Tamanini F, Willemsen R, van Unen L, Bontekoe C, Galjaard H, Oostra BA, Hoogeveen AT: Differential expression of FMR1, FXR1 and FXR2 proteins in human brain and testis. Hum Mol Genet 1997, 6(8):1315-22.
4. Cheever A, Blackwell E, Ceman S: Fragile X protein family member FXR1P is regulated by microRNAs. RNA 2010, 16(8):1530-9.
5. Bassell GJ, Warren ST: Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 2008, 60(2):201-14.
6. Louhivuori V, Louhivuori V, Vicario A, Uutela M, Rantamaki T, Louhivuori LM, Castren E, Tongiorgi E, Akerman KE, Castren ML: BDNF and TrkB in neuronal differentiation of Fmr1-knockout mouse. Neurobiol Dis 2010.
7. Brown V, Brown V, Jin P, Ceman S, Darnell JC, O'Donnell WT, Tenenbaum SA, Jin X, Feng Y, Wilkinson KD, Keene JD, Darnell RB, Warren ST: Microarray identification of FMRP-associated brain mRNAs and altered mRNA translational profiles in fragile X syndrome. Cell 2001, 107(4):477-87. (Pubitemid 33152783)
8. Malter JS, Ray BC, Westmark PR, Westmark CJ: Fragile X Syndrome and Alzheimer's Disease: Another story about APP and beta-amyloid. Curr Alzheimer Res 2010, 7(3):200-6.
9. Chen L, Yun SW, Seto J, Liu W, Toth M: The fragile X mental retardation protein binds and regulates a novel class of mRNAs containing U rich target sequences. Neuroscience 2003, 120(4):1005-17. (Pubitemid 36969801)
10. Eberhart DE, Malter HE, Feng Y, Warren ST: The fragile X mental retardation protein is a ribonucleoprotein containing both nuclear localization and nuclear export signals. Hum Mol Genet 1996, 5(8):1083-91. (Pubitemid 26318545)
11. Feng Y, Gutekunst CA, Eberhart DE, Yi H, Warren ST, Hersch SM: Fragile X mental retardation protein: nucleocytoplasmic shuttling and association with somatodendritic ribosomes. J Neurosci 1997, 17(5):1539-47. (Pubitemid 27089800)
12. Schultz-Pedersen S, Hasle H, Olsen JH, Friedrich U: Evidence of decreased risk of cancer in individuals with fragile X. Am J Med Genet 2001, 103(3):226-30.
13. Castren M, Tervonen T, Karkkainen V, Heinonen S, Castren E, Larsson K, Bakker CE, Oostra BA, Akerman K: Altered differentiation of neural stem cells in fragile X syndrome. Proc Natl Acad Sci USA 2005, 102(49):17834-9. (Pubitemid 41803583)
14. Castren M: Differentiation of neuronal cells in fragile X syndrome. Cell Cycle 2006, 5(14):1528-30.
15. Lam EW, Francis RE, Petkovic M: FOXO transcription factors: key regulators of cell fate. Biochem Soc Trans 2006, 34(Pt 5):722-6. (Pubitemid 44796405)
16. Hanahan D, Weinberg RA: The hallmarks of cancer. Cell 2000, 100(1):57-70. (Pubitemid 30046295)
17. Vivanco I, Sawyers CL: The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer 2002, 2(7):489-501. (Pubitemid 37328931)
18. Gao X, Deeb D, Hao J, Liu Y, Arbab AS, Dulchavsky SA, Gautam SC: Synthetic triterpenoids inhibit growth, induce apoptosis and suppress pro-survival Akt, mTOR and NF-{kappa}B signaling proteins in colorectal cancer cells. Anticancer Res 2010, 30(3):785-92.
19. Hu H, Qin Y, Bochorishvili G, Zhu Y, van Aelst L, Zhu JJ: Ras signaling mechanisms underlying impaired GluR1-dependent plasticity associated with fragile X syndrome. J Neurosci 2008, 28(31):7847-62.
20. Davidovic L, Huot ME, Khandjian EW: Lost once, the Fragile X Mental Retardation protein is now back onto brain polyribosomes. RNA Biol 2005, 2(1):1-3.
21. Mazroui R, Huot ME, Tremblay S, Filion C, Labelle Y, Khandjian EW: Trapping of messenger RNA by Fragile X Mental Retardation protein into cytoplasmic granules induces translation repression. Hum Mol Genet 2002, 11(24):3007-17. (Pubitemid 35414814)
22. Jin P, Zarnescu DC, Ceman S, Nakamoto M, Mowrey J, Jongens TA, Nelson DL, Moses K, Warren ST: Biochemical and genetic interaction between the fragile X mental retardation protein and the microRNA pathway. Nat Neurosci 2004, 7(2):113-7. (Pubitemid 38129786)
23. Cheever A, Ceman S: Translation regulation of mRNAs by the fragile X family of proteins through the microRNA pathway. RNA Biol 2009, 6(2):175-8.
24. Corbin F, Bouillon M, Fortin A, Morin S, Rousseau F, Khandjian EW: The fragile X mental retardation protein is associated with poly(A)+ mRNA in actively translating polyribosomes. Hum Mol Genet 1997, 6(9):1465-72. (Pubitemid 27397022)
25. Schenck A, Bardoni B, Moro A, Bagni C, Mandel JL: A highly conserved protein family interacting with the fragile X mental retardation protein (FMRP) and displaying selective interactions with FMRP-related proteins FXR1P and FXR2P. Proc Natl Acad Sci USA 2001, 98(15):8844-9. (Pubitemid 32678115)
26. Gu B, Nakamichi N, Zhang WS, Nakamura Y, Kambe Y, Fukumori R, Takuma K, Yamada K, Takarada T, Taniura H, Yoneda Y: Possible protection by notoginsenoside R1 against glutamate neurotoxicity mediated by N-methyl-D-aspartate receptors composed of an NR1/NR2B subunit assembly. J Neurosci Res 2009, 87(9):2145-56.
27. Lim JH, Booker AB, Fallon JR: Regulating fragile X gene transcription in the brain and beyond. J Cell Physiol 2005, 205(2):170-5. (Pubitemid 41428898)
28. Dobson T, Kube E, Timmerman S, Krushel LA: Identifying intrinsic and extrinsic determinants that regulate internal initiation of translation mediated by the FMR1 5' leader. BMC Mol Biol 2008, 9:89.
29. Todd PK, Mack KJ: Sensory stimulation increases cortical expression of the fragile X mental retardation protein in vivo. Brain Res Mol Brain Res 2000, 80(1):17-25. (Pubitemid 30612433)
30. Gonzalez E, McGraw TE: The Akt kinases: isoform specificity in metabolism and cancer. Cell Cycle 2009, 8(16):2502-8.
31. Du K, Montminy M: CREB is a regulatory target for the protein kinase Akt/PKB. J Biol Chem 1998, 273(49):32377-9. (Pubitemid 28557606)
32. Darnell JC, Mostovetsky O, Darnell RB: FMRP RNA targets: identification and validation. Genes Brain Behav 2005, 4(6):341-9. (Pubitemid 41192446)
33. Khalil AM, Faghihi MA, Modarresi F, Brothers SP, Wahlestedt C: A novel RNA transcript with antiapoptotic function is silenced in fragile X syndrome. PLoS One 2008, 3(1):e1486.
34. Didiot MC, Subramanian M, Flatter E, Mandel JL, Moine H: Cells lacking the fragile X mental retardation protein (FMRP) have normal RISC activity but exhibit altered stress granule assembly. Mol Biol Cell 2009, 20(1):428-37.
35. Linder B, Plottner O, Kroiss M, Hartmann E, Laggerbauer B, Meister G, Keidel E, Fischer U: Tdrd3 is a novel stress granule-associated protein interacting with the Fragile-X syndrome protein FMRP. Hum Mol Genet 2008, 17(20):3236-46.
36. Stornetta RL, Zhu JJ: Ras and Rap Signaling in Synaptic Plasticity and Mental Disorders. Neuroscientist 2010.
37. Sharma A, Hoeffer CA, Takayasu Y, Miyawaki T, McBride SM, Klann E, Zukin RS: Dysregulation of mTOR signaling in fragile X syndrome. J Neurosci 2010, 30(2):694-702.
38. Narayanan U, Nalavadi V, Nakamoto M, Thomas G, Ceman S, Bassell GJ, Warren ST: S6K1 phosphorylates and regulates fragile X mental retardation protein (FMRP) with the neuronal protein synthesis-dependent mammalian target of rapamycin (mTOR) signaling cascade. J Biol Chem 2008, 283(27):18478-82.
39. Gross C, Nakamoto M, Yao X, Chan CB, Yim SY, Ye K, Warren ST, Bassell GJ: Excess phosphoinositide 3-kinase subunit synthesis and activity as a novel therapeutic target in fragile X syndrome. J Neurosci 2010, 30(32):10624-38.
40. Hawkins PT, Anderson KE, Davidson K, Stephens LR: Signalling through Class I PI3Ks in mammalian cells. Biochem Soc Trans 2006, 34(Pt 5):647-62. (Pubitemid 44796393)
41. Peavy RD, Sorensen SD, Conn PJ: Differential regulation of metabotropic glutamate receptor 5-mediated phosphoinositide hydrolysis and extracellular signal-regulated kinase responses by protein kinase C in cultured astrocytes. J Neurochem 2002, 83(1):110-8.
42. Ronesi JA, Huber KM: Homer interactions are necessary for metabotropic glutamate receptor-induced long-term depression and translational activation. J Neurosci 2008, 28(2):543-7.
43. Chiang CW, Yan L, Yang E: Phosphatases and regulation of cell death. Methods Enzymol 2008, 446:237-57.
44. Freilinger A, Rosner M, Krupitza G, Nishino M, Lubec G, Korsmeyer SJ, Hengstschlager M: Tuberin activates the proapoptotic molecule BAD. Oncogene 2006, 25(49):6467-79. (Pubitemid 44607079)
45. Leverrier Y, Thomas J, Mathieu AL, Low W, Blanquier B, Marvel J: Role of PI3-kinase in Bcl-X induction and apoptosis inhibition mediated by IL-3 or IGF-1 in Baf-3 cells. Cell Death Differ 1999, 6(3):290-6. (Pubitemid 29145833)
46. Yang FC, Kapur R, King AJ, Tao W, Kim C, Borneo J, Breese R, Marshall M, Dinauer MC, Williams DA: Rac2 stimulates Akt activation affecting BAD/Bcl-XL expression while mediating survival and actin function in primary mast cells. Immunity 2000, 12(5):557-68.
47. Horbinski C, Chu CT: Kinase signaling cascades in the mitochondrion: a matter of life or death. Free Radic Biol Med 2005, 38(1):2-11. (Pubitemid 39626903)
48. Grad JM, Zeng XR, Boise LH: Regulation of Bcl-xL: a little bit of this and a little bit of STAT. Curr Opin Oncol 2000, 12(6):543-9. (Pubitemid 32039653)
49. Downward J: Mechanisms and consequences of activation of protein kinase B/Akt. Curr Opin Cell Biol 1998, 10(2):262-7.
50. Ramljak D, Coticchia CM, Nishanian TG, Saji M, Ringel MD, Conzen SD, Dickson RB: Epidermal growth factor inhibition of c-Myc-mediated apoptosis through Akt and Erk involves Bcl-xL upregulation in mammary epithelial cells. Exp Cell Res 2003, 287(2):397-410. (Pubitemid 37323851)
51. Elliott MJ, Murphy KM, Stribinskiene L, Ranganathan V, Sturges E, Farnsworth ML, Lock RB: Bcl-2 inhibits early apoptotic events and reveals post-mitotic multinucleation without affecting cell cycle arrest in human epithelial tumor cells exposed to etoposide. Cancer Chemother Pharmacol 1999, 44(1):1-11. (Pubitemid 29246319)